Skip to main content
Temporal Gene Control

Tamoxifen Inducible Cre

Since 1998, ingenious targeting laboratory has incorporated tamoxifen inducible Cre systems into hundreds of conditional knockout and knockin projects, providing researchers with precise temporal control over gene manipulation in adult animals.

Tamoxifen inducible Cre (CreERT2) enables gene deletion at any chosen time point, avoiding developmental compensation, bypassing embryonic lethality, and enabling study of gene function in mature tissues.

2,500+
Projects Completed
800+
Publications
26+
Years Experience
100%
Success Rate

How the CreERT2 System Works

1

CreERT2 Fusion Protein

Cre recombinase fused to mutant estrogen receptor that prevents binding of endogenous estrogen but retains affinity for synthetic ligands.

2

Cytoplasmic Sequestration

Without ligand, ERT2 domain associates with HSP90, sequestering CreERT2 in cytoplasm away from nuclear DNA.

3

Tamoxifen Induction

Tamoxifen administration displaces HSP90 and allows nuclear translocation of CreERT2, enabling LoxP recombination.

4

Permanent Recombination

CreERT2 activity is transient once tamoxifen clears, but recombination events are permanent genetic changes.

Advantages of Temporal Control

Bypass Embryonic Lethality

Genes essential for development can be deleted in adults after normal development is complete.

Avoid Developmental Compensation

Constitutive gene loss may trigger compensatory mechanisms. Adult deletion avoids this adaptation.

Defined Deletion Timing

Know exactly when gene deletion occurs relative to experimental manipulation.

Control Group Simplicity

Same genotype with and without tamoxifen provides matched controls.

Tamoxifen Administration Routes

Intraperitoneal Injection

Most common method. Tamoxifen dissolved in corn oil. Typical doses 75 to 100 mg/kg body weight.

Oral Gavage

Direct delivery to stomach. Similar dosing to IP.

Tamoxifen Chow

Convenient for extended dosing. 250 to 500 mg tamoxifen per kg diet. Less precise timing.

Topical (4 OHT)

4 hydroxytamoxifen applied topically for skin specific studies.

Tissue Specific Inducible Cre Lines

Ubiquitous

  • Rosa26 CreERT2Ubiquitous
  • UBC CreERT2Ubiquitin C promoter, widespread

Neuronal

  • CamKII CreERT2Forebrain excitatory neurons
  • Thy1 CreERT2Neurons
  • Nestin CreERT2Neural progenitors

Metabolic

  • Albumin CreERT2Hepatocytes
  • Pdx1 CreERT2Pancreatic beta cells
  • Adiponectin CreERT2Adipocytes

Cardiovascular

  • Myh6 CreERT2Cardiomyocytes
  • Cdh5 CreERT2Endothelial cells

What Researchers Say

I've been working with iTL over the past 5 years in the production of 3 different genetically altered mice. Not only did iTL help in the design of the mice, but the entire process was transparent with the opportunity at any time along the way to discuss my questions or concerns with scientists who had significant insight into the process. The mice were delivered on time, as billed!

Raghu Mirmira, MD, PhD

University of Chicago

✦ New for 2026

Breeding Scheme Architect

Plan complex multi-allele breeding strategies, calculate expected genotype ratios, and estimate time to experimental cohorts—all before starting your project.

Visualize multi-generation breeding paths
Calculate Mendelian ratios automatically
Estimate timeline to study-ready cohorts

Free Research Tool

No account required

Allele 1Gene-flox (conditional)
Allele 2Cre-driver (tissue-specific)
TargetHomozygous knockout

→ 3 generations to target genotype

Start Your Inducible Cre Project

Our scientific consultants can help you select the optimal inducible Cre system, establish tamoxifen dosing protocols, and design floxed alleles for temporal gene control.

Frequently asked questions

CreERT2 is a fusion protein combining Cre recombinase with a modified estrogen receptor that is inactive until tamoxifen administration. Tamoxifen binds to the receptor, causing translocation to the nucleus where Cre becomes active and excises LoxP flanked sequences. This enables temporal control over gene deletion.

Regular Cre is constitutively active in cells where it is expressed, causing immediate gene deletion. CreERT2 remains inactive until tamoxifen administration, allowing precise temporal control. This is essential for studying gene function in adults without developmental effects.

Tamoxifen is typically administered via intraperitoneal injection at doses of 75 to 200 mg/kg body weight. Multiple injections over several days improve recombination efficiency. Tamoxifen can also be administered via oral gavage or in food.

Recombination typically occurs within 2 to 7 days after tamoxifen administration. Peak recombination is usually observed 3 to 5 days post treatment. Some tissues may require longer or multiple doses for efficient recombination.

No. CreERT2 causes permanent DNA excision (deletion), which is irreversible. Once LoxP flanked sequences are excised, they cannot be restored. For reversible gene regulation, use doxycycline inducible (Tet) systems.

Lab Signals

Monitor Your Inducible Cre Project

Get real-time updates on your CreERT2 model development, floxed allele validation, and tamoxifen induction protocol optimization.

Subscribe Free